These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31378985)

  • 21. Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019.
    Tovoli F; Casadei-Gardini A; Benevento F; Piscaglia F
    Dig Liver Dis; 2019 Aug; 51(8):1067-1073. PubMed ID: 31208929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy of Hepatocellular Carcinoma.
    Heinrich B; Czauderna C; Marquardt JU
    Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma.
    Nishida N; Kudo M
    Dig Dis; 2017; 35(6):618-622. PubMed ID: 29040995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
    Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
    J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications.
    Cariani E; Missale G
    Liver Int; 2019 Sep; 39(9):1608-1621. PubMed ID: 31314948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder.
    Chang E; Sabichi AL; Sada YH
    J Immunother; 2017 Apr; 40(3):114-116. PubMed ID: 28234667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy for hepatocellular carcinoma: Current and future.
    Johnston MP; Khakoo SI
    World J Gastroenterol; 2019 Jun; 25(24):2977-2989. PubMed ID: 31293335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Toxicities of immune checkpoint inhibitors and their management].
    Kostine M; Marabelle A; Schaeverbeke T; Kfoury M
    Med Sci (Paris); 2019 Dec; 35(12):949-956. PubMed ID: 31903899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
    Choi B; McBride A; Scott AJ
    Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
    Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
    Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.
    Brown ZJ; Heinrich B; Steinberg SM; Yu SJ; Greten TF
    J Immunother Cancer; 2017 Nov; 5(1):93. PubMed ID: 29157287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice.
    Parthymos I; Liamis G; Dounousi E; Pentheroudakis G; Mauri D; Zarkavelis G; Florentin M
    Crit Rev Oncol Hematol; 2020 Jul; 151():102979. PubMed ID: 32480349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
    Fernandes S; Varlamov EV; McCartney S; Fleseriu M
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
    Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
    Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
    Moreno-Cubero E; Larrubia JR
    World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy.
    Jiang Y; Han QJ; Zhang J
    World J Gastroenterol; 2019 Jul; 25(25):3151-3167. PubMed ID: 31333308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.
    Greten TF; Lai CW; Li G; Staveley-O'Carroll KF
    Gastroenterology; 2019 Jan; 156(2):510-524. PubMed ID: 30287171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An overview of the toxicities of checkpoint inhibitors in older patients with cancer.
    Alkharabsheh O; Kannarkatt P; Kannarkatt J; Karapetyan L; Laird-Fick HS; Al-Janadi A
    J Geriatr Oncol; 2018 Sep; 9(5):451-458. PubMed ID: 29567089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.